A Study of HBI-8000 (Tucidinostat) With Pembrolizumab in Non-Small Cell Lung Cancer
Status:
Not yet recruiting
Trial end date:
2025-02-01
Target enrollment:
Participant gender:
Summary
This Phase 2 study evaluates HBI-8000, a histone deacetylase inhibitor (HDACi) in combination
with pembrolizumab for the treatment of patients with advanced or metastatic non-small cell
lung cancer who possess programmed death ligand 1 (PD-L1) expression Tumor Proportion Score
(TPS) of 1% or greater.